CN101766695B - 一种穴位眼贴及其制备方法和应用 - Google Patents
一种穴位眼贴及其制备方法和应用 Download PDFInfo
- Publication number
- CN101766695B CN101766695B CN2009100003437A CN200910000343A CN101766695B CN 101766695 B CN101766695 B CN 101766695B CN 2009100003437 A CN2009100003437 A CN 2009100003437A CN 200910000343 A CN200910000343 A CN 200910000343A CN 101766695 B CN101766695 B CN 101766695B
- Authority
- CN
- China
- Prior art keywords
- semen
- eye mask
- medicine
- drug
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 182
- 210000000582 semen Anatomy 0.000 claims abstract description 103
- 229940079593 drug Drugs 0.000 claims abstract description 93
- 238000003860 storage Methods 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims description 54
- 241000628997 Flos Species 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 22
- 238000012545 processing Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 abstract description 107
- 239000010410 layer Substances 0.000 abstract description 33
- 238000011282 treatment Methods 0.000 abstract description 31
- 230000004410 intraocular pressure Effects 0.000 abstract description 29
- 239000000839 emulsion Substances 0.000 abstract description 26
- 238000001467 acupuncture Methods 0.000 abstract description 16
- 239000011248 coating agent Substances 0.000 abstract description 14
- 238000000576 coating method Methods 0.000 abstract description 14
- 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract description 11
- 210000004204 blood vessel Anatomy 0.000 abstract description 9
- 210000003205 muscle Anatomy 0.000 abstract description 9
- 206010047513 Vision blurred Diseases 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 6
- 210000005036 nerve Anatomy 0.000 abstract description 5
- 239000011241 protective layer Substances 0.000 abstract description 5
- 201000010041 presbyopia Diseases 0.000 abstract description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 2
- 241000202807 Glycyrrhiza Species 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 241000110637 Cuscuta chinensis Species 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 241000195955 Equisetum hyemale Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241001499733 Plantago asiatica Species 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000012676 herbal extract Substances 0.000 abstract 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 230000004423 myopia development Effects 0.000 abstract 1
- 239000011858 nanopowder Substances 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 229920006267 polyester film Polymers 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 63
- 230000017531 blood circulation Effects 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 230000004089 microcirculation Effects 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000004438 eyesight Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000201295 Euphrasia Species 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 229920002799 BoPET Polymers 0.000 description 9
- 239000005041 Mylar™ Substances 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000004744 fabric Substances 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 208000001491 myopia Diseases 0.000 description 8
- 239000003961 penetration enhancing agent Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000002177 Cataract Diseases 0.000 description 7
- 208000010412 Glaucoma Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000004379 myopia Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000000080 wetting agent Substances 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 244000178870 Lavandula angustifolia Species 0.000 description 5
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000475481 Nebula Species 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 235000013599 spices Nutrition 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 4
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 210000001742 aqueous humor Anatomy 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 208000005494 xerophthalmia Diseases 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 210000000589 cicatrix Anatomy 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000000695 crystalline len Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000009978 visual deterioration Effects 0.000 description 3
- 238000004078 waterproofing Methods 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- 206010009185 Ciliary muscle spasm Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042170 Strangury Diseases 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- -1 acrylic ester Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 229940124579 cold medicine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000003446 pia mater Anatomy 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 241000195952 Equisetaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004515 progressive myopia Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Images
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100003437A CN101766695B (zh) | 2009-01-06 | 2009-01-06 | 一种穴位眼贴及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100003437A CN101766695B (zh) | 2009-01-06 | 2009-01-06 | 一种穴位眼贴及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101766695A CN101766695A (zh) | 2010-07-07 |
CN101766695B true CN101766695B (zh) | 2012-07-04 |
Family
ID=42499896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100003437A Active CN101766695B (zh) | 2009-01-06 | 2009-01-06 | 一种穴位眼贴及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101766695B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2494708C1 (ru) * | 2012-06-09 | 2013-10-10 | Сергей Анатольевич Обрубов | Способ лечения прогрессирующей близорукости у детей |
CN103349125A (zh) * | 2013-07-22 | 2013-10-16 | 北京绿源求证科技发展有限责任公司 | 一种改善睡眠的食品养生茶冲剂 |
CN104435442A (zh) * | 2014-11-01 | 2015-03-25 | 项玉荣 | 一种治疗阴虚湿热型干眼症的中药制剂 |
CN106074966A (zh) * | 2016-06-22 | 2016-11-09 | 王金国 | 一种应用于青少年青光眼的眼贴 |
CN106421346B (zh) * | 2016-11-12 | 2021-02-05 | 南阳医学高等专科学校 | 一种结合针灸治疗青光眼的中药组合物及其制备方法 |
CN107875289A (zh) * | 2017-06-21 | 2018-04-06 | 苏州雅致堂草本科技有限公司 | 一种保护视力的纯中药水凝胶护眼贴膜的制备方法 |
CN107519280A (zh) * | 2017-10-23 | 2017-12-29 | 陕西中美天顺药业有限公司 | 一种用于视疲劳及眼部皮肤护理的中药贴剂及其制备方法 |
CN108498320A (zh) * | 2018-03-08 | 2018-09-07 | 河南佑眼视力康复有限公司 | 一种用于调理近视的经络管 |
CN108686129A (zh) * | 2018-08-13 | 2018-10-23 | 河南中医药大学 | 一种治疗干眼症的中药甘参菊精油眼贴 |
CN109172743A (zh) * | 2018-09-19 | 2019-01-11 | 广州市醒目堂生物科技有限公司 | 一种眼用制剂及制备方法 |
CN109568546A (zh) * | 2019-02-01 | 2019-04-05 | 大连大学 | 一种治疗类风湿性关节炎的中药组合物及其贴剂的制备方法 |
CN109758533A (zh) * | 2019-03-18 | 2019-05-17 | 陈培培 | 一种用于护眼的药物组合物及其制备方法与用途 |
CN111544575A (zh) * | 2020-04-30 | 2020-08-18 | 广州市醒目医药科技有限公司 | 一种护眼贴及其制备方法和应用 |
CN115364143A (zh) * | 2022-08-09 | 2022-11-22 | 重庆康视美科技有限公司 | 一种功能性眼贴及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1494901A (zh) * | 2002-08-27 | 2004-05-12 | 一种眼明轻松贴及其制备方法 | |
CN1840126A (zh) * | 2006-02-06 | 2006-10-04 | 李功淮 | 一种治疗弱视和近视的中药 |
-
2009
- 2009-01-06 CN CN2009100003437A patent/CN101766695B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1494901A (zh) * | 2002-08-27 | 2004-05-12 | 一种眼明轻松贴及其制备方法 | |
CN1840126A (zh) * | 2006-02-06 | 2006-10-04 | 李功淮 | 一种治疗弱视和近视的中药 |
Non-Patent Citations (1)
Title |
---|
李迎舒等.中药治疗青少年近视314例疗效观察.《北京中医》.1997,(第6期),37. * |
Also Published As
Publication number | Publication date |
---|---|
CN101766695A (zh) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101766695B (zh) | 一种穴位眼贴及其制备方法和应用 | |
CN1214785C (zh) | 一种用于保护眼睛的透皮控穴位贴片及其制备方法 | |
CN102631558A (zh) | 一种用于治疗眼疾的中成药及其制备方法 | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
CN103520621A (zh) | 一种治疗老年性白内障的中药组合物及其制备方法 | |
CN104758806A (zh) | 一种治疗冠心病的煎膏剂及其制备方法 | |
CN102600386A (zh) | 一种治疗眼科炎症的中药制剂及其制备方法 | |
CN102362924B (zh) | 一种治疗眼科疾病的药物组合物及其制备方法 | |
CN104127702A (zh) | 一种治疗急性视神经炎的中药制剂及其制备方法 | |
CN103169765A (zh) | 一种杜仲籽油红曲复方软胶囊制剂及其制备方法 | |
CN105168446A (zh) | 一种治疗眼部疾病的中药组合物、眼部美容添加包及其制备方法 | |
CN1263485C (zh) | 五子明目丸及其制备工艺 | |
CN111329915B (zh) | 一种用于缓解老年人视疲劳的组合物及其亲水凝胶 | |
CN2865632Y (zh) | 中药眼贴 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102935162B (zh) | 一种用于球后视神经炎症的药丸及制备方法 | |
CN103525640B (zh) | 一种活力壮阳酒 | |
CN105194427A (zh) | 一种治疗干眼症的中药组合物及其制备方法 | |
CN102058841B (zh) | 一种治疗高血压的脐部外用药及其制备方法 | |
CN100488494C (zh) | 一种眼科中药复方制剂及提取方法、制备方法、新用途 | |
CN107137603A (zh) | 一种缓解视疲劳的中药组合物、制剂及其制备方法 | |
CN111228396B (zh) | 一种用于缓解中青年视疲劳的组合物、眼贴及其制备方法 | |
CN114796358B (zh) | 一种缓解视疲劳的中药组合物及其制备方法和应用 | |
CN102755549A (zh) | 一种治疗白内障的药物及其制备方法 | |
CN102225105B (zh) | 一种治疗偏头痛的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20150625 Granted publication date: 20120704 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20160625 Granted publication date: 20120704 |
|
PP01 | Preservation of patent right |
Effective date of registration: 20160625 Granted publication date: 20120704 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20161225 Granted publication date: 20120704 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20161225 Granted publication date: 20120704 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20170625 Granted publication date: 20120704 |
|
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20180622 Granted publication date: 20120704 |